Extended exposure to lower doses of these drugs can induce drug resistance, as exemplified by cells of the TP53‐Dox line, produced by subchronic Dox treatment of cancer cells (SW48/TP53 TP53 R273H/+) heterozygous for the corresponding TP53 missense point mutation20, 22 (Figure 1B). This evidence concerns the gene TP53 and cancer.